Περίληψη:
The first joint European Society for Medical Oncology (ESMO), European SocieTy for Radiotherapy & Oncology (ESTRO) and European Society of Gynaecological Oncology (ESGO) consensus conference on endometrial cancer was held on 11-13 December 2014 in Milan, Italy, and comprised a multidisciplinary panel of 40 leading experts in the management of endometrial cancer. Before the conference, the expert panel prepared three clinically relevant questions about endometrial cancer relating to the following four areas: prevention and screening, surgery, adjuvant treatment and advanced and recurrent disease. All relevant scientific literature, as identified by the experts, was reviewed in advance. During the consensus conference, the panel developed recommendations for each specific question and a consensus was reached. Results of this consensus conference, together with a summary of evidence supporting each recommendation, are detailed in this article. All participants have approved this final article. © The Author 2015.
Συγγραφείς:
Colombo, N.
Creutzberg, C.
Amant, F.
Bosse, T.
González-Martón, A.
Ledermann, J.
Marth, C.
Nout, R.
Querleu, D.
Mirza, M.R.
Sessa, C.
Abal, M.
Altundag, O.
Banerjee, S.
Casado, A.
De Agustín, L.C.
Cibula, D.
Del Campo, J.-M.
Emons, G.
Goffin, F.
González-Martín, A.
Greggi, S.
Haie-Meder, C.
Katsaros, D.
Kesic, V.
Kurzeder, C.
Lax, S.
Lécuru, F.
Levy, T.
Lorusso, D.
Mäenpää, J.
Matias-Guiu, X.
Morice, P.
Nijman, H.W.
Powell, M.
Reed, N.
Rodolakis, A.
Salvesen, H.
Sehouli, J.
Taylor, A.
Westermann, A.
Zeimet, A.G.
The ESMO-ESGO-ESTRO Endometrial Consensus Conference Working Group
Λέξεις-κλειδιά:
anastrozole; bevacizumab; carboplatin; cisplatin; doxorubicin; estrogen receptor; fulvestrant; gestagen; ixabepilone; K ras protein; levonorgestrel; mammalian target of rapamycin; medroxyprogesterone acetate; megestrol acetate; mitogen activated protein kinase; Notch receptor; paclitaxel; phosphatidylinositol 3 kinase; phosphatidylinositol 3,4,5 trisphosphate 3 phosphatase; progesterone receptor; protein kinase B; somatomedin receptor; tamoxifen; temsirolimus; transforming growth factor beta; vasculotropin; vasculotropin receptor, advanced cancer; angiogenesis; Article; body mass; bone marrow toxicity; brachytherapy; breast cancer; cancer chemotherapy; cancer grading; cancer incidence; cancer prevention; cancer recurrence; cancer risk; cancer screening; cancer specific survival; cancer staging; cancer susceptibility; cohort analysis; computer assisted emission tomography; consensus development; cost effectiveness analysis; differential diagnosis; disease association; disease free survival; drug efficacy; echography; endometrial intraepithelial carcinoma; endometrioid endometrial cancer; endometrium biopsy; endometrium cancer; external beam radiotherapy; hereditary nonpolyposis colorectal cancer; human; hypertension; hysteroscopy; immunohistochemistry; infertility; intensity modulated radiation therapy; intrauterine contraceptive device; laparotomy; lymph node dissection; meta analysis (topic); metabolic syndrome X; microsatellite instability; nausea; non insulin dependent diabetes mellitus; nuclear magnetic resonance imaging; obesity; observational study; ovary cancer; ovary metastasis; ovary polycystic disease; overall survival; pathogenesis; peripheral neuropathy; phase 1 clinical trial (topic); phase 2 clinical trial (topic); phase 3 clinical trial (topic); physical activity; premenopause; preoperative period; priority journal; prospective study; quality of life; randomized controlled trial (topic); risk reduction; salpingooophorectomy; signal transduction; treatment response; tumor volume; vaginal hysterectomy; vomiting; consensus development; early cancer diagnosis; Endometrial Neoplasms; female; follow up; mass screening; multimodality cancer therapy; practice guideline, Combined Modality Therapy; Early Detection of Cancer; Endometrial Neoplasms; Female; Follow-Up Studies; Humans; Mass Screening; Practice Guidelines as Topic
